Safety and immunogenicity of 4CMenB and MenACWY-CRM meningococcal vaccines when administered concomitantly in healthy adolescents: A phase 3b, randomized, observer-blind study Authors: Alejandro Hoberman, Jibran Atwi, Peter Silas, Rosa Prato, Samantha Bosis, Judith M Martin, Isabelle Lechevin, Mariapia Possidente, Sara Manzella, Luca Moraschini, Maria Lattanzi, Pavitra Keshavan Published: 2026 ABSTRACT ABSTRACTMeningococcal vaccination of adolescents/young adults is recommended in various countries, including the United States (US). This phase 3b, observer-blind study (NCT04318548) evaluated the safety, reactogenicity, and immunogenicity of serogroup B vaccine, 4CMenB, and quadrivalent conjugate vaccine, MenACWY-CRM, when co-administered to healthy individuals aged 16–18 y, as per US Advisory Committee on Immunization Practices recommendations. Adolescents, who had received MenACWY vaccination ≥4 y previously, were randomized (N = 940; 1:1:1) to one of three groups to assess co-administration versus 4CMenB and MenACWY-CRM administered alone. Co-primary objectives were to demonstrate the non-inferiority of antibody responses after concomitant administration to antibody responses after 4CMenB (two doses administered 2 months apart) and MenACWY-CRM (single dose), as measured by human serum bactericidal assay (hSBA). Vaccine safety and reactogenicity were assessed as another primary objective. The co-primary endpoints were met: the lower limit of 2-sided 95% confidence intervals for all between-group ratios of hSBA geometric mean titers was >0.5 for the concomitant administration group versus 4CMenB group and MenACWY-CRM group. hSBA data after two 4CMenB doses and one MenACWY-CRM dose showed comparable between-group geometric mean ratios versus baseline, and percentages of participants with 4-fold rises in titers and titers ≥lower limit of quantitation. The safety profile of 4CMenB co-administered with MenACWY-CRM was comparable with that of 4CMenB administered alone. In conclusion, 4CMenB and MenACWY-CRM co-administration was well tolerated in adolescents aged 16–18 y and immune responses were comparable versus administration of each vaccine alone, which is consistent with a previous study of co-administration in infants.KEYWORDS: 4CMenB, adolescents, co-administration, MenACWY-CRM, meningococcal disease, Neisseria meningitidis, serogroup B, vaccine Introduction The bacterium Neisseria meningitidis is responsible for invasive meningococcal disease (IMD), which is associated with a rapid onset, severe clinical presentations often followed by disabling sequelae, and a fatal outcome in 4–20% of cases.1,2 Most IMD cases are caused by six serogroups (A, B, C, W, X, Y) that have variable distribution both geographically and over time.3 The incidence of IMD peaks in infants, children aged 1–4 y, and adolescents/young adults,4,5 and the incidence in older adults is reported to be increasing in some countries.4,6 Moreover, adolescents/young adults may have higher meningococcal carriage rates than younger age groups, increasing the IMD risk and likelihood of transmission.7 The four-component 4CMenB vaccine (Bexsero, GSK) was licensed in the European Union (EU) in 2013 and the United States (US) in 2015, and is now registered in over 50 countries.8,9 4CMenB includes three recombinant protein antigens, Neisseria adhesin A (NadA), neisserial heparin-binding antigen (NHBA), and factor H binding protein (fHbp), and detergent-extracted outer membrane vesicles from a New Zealand outbreak strain, containing Porin A (PorA) as the immunodominant antigen.8,10 The quadrivalent serogroups A, C, W, Y polysaccharide vaccine conjugated to a nontoxic mutant of diphtheria toxin (MenACWY-CRM; Menveo, GSK) was first licensed in 2010 in the US, Canada, and the EU11 and is also registered in over 50 countries (GSK, data on file). More than a decade of clinical and real-world experience confirms the benefit of 4CMenB and MenACWY-CRM vaccination across different age groups.9,11 A study conducted in 750 healthy infants demonstrated non-inferiority of immune responses after 4CMenB and MenACWY-CRM co-administration versus separate administration of the vaccines, and concomitant administration was well tolerated.12 Co-administration of 4CMenB with MenACWY is approved in most countries that include 4CMenB in their national infant immunization program.9,13 There are national recommendations for both MenB and MenACWY vaccination of adolescents in several European countries and regional recommendations in Australia, Italy, and Canada.9 In the US, the Advisory Committee on Immunization Practices (ACIP) recommends (as of December 2025) routine MenACWY vaccination for adolescents aged 11 or 12 y, with a booster dose at 16 y.14 ACIP also recommends routine vaccination with MenACWY for persons aged ≥2 months at increased risk for meningococcal disease caused by serogroups A, C, W, or Y. MenB vaccination is recommended for adolescents and young adults aged 16–23 y (preferred age, 16–18 y) on the basis of shared clinical decision-making and routinely for persons aged ≥10 y at increased risk for meningococcal disease caused by MenB.14 The ACIP recommendations specify that MenACWY and MenB vaccines can be co-administered at different injection sites, if feasible.14 Two pentavalent meningococcal vaccines are recommended in the US for the same population groups as for MenB vaccines.15,16 While data on co-administration are available in infants,12 no clinical study data were available on the concomitant use of 4CMenB and MenACWY-CRM in adolescents. As part of a commitment in the US following accelerated approval of 4CMenB in 2015, the present study was designed to evaluate the safety, reactogenicity, and immunogenicity of 4CMenB and MenACWY-CRM when co-administered to individuals aged 16–18 y, in accordance with ACIP age group recommendations. Materials and methods Study design and participants This phase 3b, randomized, observer-blind study was conducted in 48 centers in the US and four centers in Italy between August 2020 and November 2023 (ClinicalTrials.gov: NCT04318548). The study adhered to the Declaration of Helsinki, Council for International Organizations of Medical Sciences International Ethical guidelines, and Good Clinical Practice guidelines. Advarra IRB (central institutional review board) in the US and Comitato Etico Territoriale Lombardia 3 (ethics committee) in Italy granted approval. In the US, the initial approval was followed by annual continuing reviews. In Italy, subsequent re-approvals were obtained for each of the seven protocol amendments. Participants were healthy, aged 16–18 y, and had received a single MenACWY dose (Menveo, GSK, or Menactra, Sanofi Pasteur Inc.) at least 4 y before study start. Written informed consent was provided by all participants aged 18 y or older. Those aged under 18 y provided assent and written informed consent was provided by their parents or legally acceptable representatives. Re-consent for continued participation was to be obtained from participants who became adults during the study. Exclusion criteria included prior meningococcal disease or contact with an individual with confirmed meningococcal disease within the previous 60 d, previous vaccination with a MenB vaccine, or abnormal immune system function. Further inclusion and exclusion criteria are listed in the study protocol (https://www.gsk-studyregister.com/en/trial-details/?id=205419). Participants were randomized (1:1:1 ratio) to one of three parallel groups: the 4CMenB+MenACWY group, 4CMenB group, or MenACWY group. The 4CMenB+MenACWY group received 4CMenB concomitantly with MenACWY-CRM at study day 1, 4CMenB at day 61, and placebo at day 91. The 4CMenB group received 4CMenB concomitantly with placebo at day 1, 4CMenB at day 61, and MenACWY-CRM at day 91. The MenACWY group received MenACWY-CRM concomitantly with placebo at day 1, and 4CMenB at days 61 and 91. Allocation to study group at each site was conducted via a central randomization system using a minimization procedure accounting for center. There were five study visits, at days 1, 31, 61, 91, and (for collection of electronic diaries) day 121, with safety follow-up planned for 12 months after the last dose. A protocol amendment allowed for extended visit windows, due to the COVID-19 pandemic, and a safety follow-up period of 6 months after the last dose because of the recent availability of extensive safety data from a large US trial of adolescents and young adults.17,18 The study was observer blinded, i.e., participants, their caregivers, study evaluators, and laboratory personnel were unaware of the vaccine administered. Vaccine and placebo injections were prepared and administered by unblinded trial staff who did not participate in clinical evaluations or assays. 4CMenB and MenACWY-CRM vaccine compositions were described previously.19,20 Placebo was a 0.9% saline solution (0.6–0.8 mL doses). Vaccines were prepared as 0.5 mL doses and administered intramuscularly into the deltoid region, preferably of the non-dominant arm. Separate arms were injected when two injections were administered at the same visit to distinguish local adverse events (AEs) after concomitant vaccination. Study objectives Safety and reactogenicity of 4CMenB and MenACWY-CRM, when administered concomitantly or alone, were assessed as a primary objective. Other primary study objectives were to demonstrate non-inferiority of the antibody response to 4CMenB and MenACWY-CRM given concomitantly compared to antibody responses to either vaccine alone, as measured by human serum bactericidal assay (hSBA). Non-inferiority would be demonstrated if the lower limits (LLs) of the 2-sided 95% confidence intervals (CIs) for the between-group ratios of hSBA geometric mean antibody titers (GMTs) (4CMenB+MenACWY group versus 4CMenB group and 4CMenB+MenACWY group versus MenACWY group) were >0.5 for all four MenB indicator strains 1 month after the second 4CMenB dose and for serogroups A, C, W, and Y 1 month after MenACWY-CRM vaccination.21 Immune responses to 4CMenB and MenACWY-CRM when administered concomitantly versus alone were assessed as secondary objectives. Results are presented for endpoints generated by hSBA. The analysis of antibody concentrations against serogroups A, C, W, and Y measured by electrochemiluminescence (ECL) assay, a powered secondary objective, is ongoing. Data on all primary and secondary endpoints, apart from the ECL assay data, are available at https://www.gsk-studyregister.com/en/ (study identifier 205419). This will be updated to include ECL assay data when available. Immunogenicity evaluation Blood samples (~20 mL) were collected before the first dose on day 1, day 31 (1 month after the first vaccination), and day 91 (1 month after the second vaccination). Immunogenicity data from the 4CMenB+MenACWY and 4CMenB groups were evaluated at day 31 and day 91. Immunogenicity data after the single MenACWY-CRM dose in the MenACWY group were evaluated at day 31. Vaccine immunogenicity was assessed by hSBA. For 4CMenB, immunogenicity was assessed against four MenB indicator strains, each expressing one of the four vaccine antigens (NadA, NHBA, fHbp, or PorA).19 For MenACWY-CRM, immunogenicity was assessed against serogroups A, C, W, and Y. Immunogenicity endpoints included hSBA GMTs, geometric mean ratios (GMRs) post-vaccination compared to baseline, and percentage of participants with a four-fold rise in hSBA titer and with hSBA titers ≥lower limit of quantitation (LLOQ). Four-fold rise in hSBA titer, LLOQ, and hSBA assay limits are defined in the Supplementary Material. Safety evaluation Participants were observed for at least 30 minutes after each vaccine dose for immediate AEs. Solicited local AEs (injection site pain, induration, swelling, and erythema) and systemic AEs (headache, fatigue, nausea, myalgia, arthralgia, and fever) were reported by participants on electronic diaries for 7 d following each vaccine dose. The severity of solicited AEs was categorized as mild, moderate, or severe. Severe was defined as preventing normal everyday activity, apart from severe induration, swelling, and erythema, which were defined as diameter >100 mm. Fever was defined as body temperature ≥38.0°C and severe fever as body temperature ≥40°C. Percentages of participants with unsolicited AEs (including serious AEs [SAEs]), AEs leading to withdrawal, and medically attended AEs were recorded up to 30 d after each vaccination. SAEs, AEs leading to withdrawal, medically attended AEs, and AEs of special interest (including arthritis and potential immune-mediated diseases22) were recorded during the 9-month study period. SAEs, AEs leading to withdrawal, and AEs of special interest throughout the extended follow-up were also assessed for participants who were followed for 12 months after administration of the last study dose. The causal relationship to vaccination of unsolicited AEs, SAEs, and AEs of special interest was assessed by study investigators. The approach used in this study to evaluate safety is consistent with that used in previous 4CMenB studies.19 Statistical analyses The target sample size was 750 participants evaluable for immunogenicity (250 per study group) to have an overall power of 90% or more. The sample size calculation was based on hSBA titer data on the immune response to 4CMenB in two previous studies23,24 and on the immune response to MenACWY-CRM in two studies.25,26 Estimating that approximately 20% of enrolled participants might withdraw or not be evaluable for immunogenicity, the target sample size to be enrolled was 945 participants (315 per group), as calculated based on results from previous studies,23-26 the non-inferiority margin of 0.5, and an expected GMT ratio of 0.9. The safety primary objective was descriptive and the safety analyses were conducted on participants who received at least one dose of study treatment. The two co-primary immunogenicity objectives were achieved if all non-inferiority hypotheses were demonstrated simultaneously. The statistical hypotheses and analyses assumed that logarithmically (base of 10) transformed hSBA titers follow a normal distribution. For the demonstration of non-inferiority of concomitant 4CMenB and MenACWY-CRM to either 4CMenB alone or MenACWY-CRM alone, null (not non-inferiority) and alternative (non-inferiority) hypotheses were tested simultaneously, to control for the type I error rate. Hypotheses were tested simultaneously on all four MenB indicator strains and A, C, W, and Y serogroups. The secondary immunogenicity objectives were analyzed with two-sided 95% Clopper-Pearson CIs.27 Primary immunogenicity analyses were conducted on the per-protocol set, which included all participants who received at least one dose of study vaccine and had post-vaccination data and excluded participants with protocol deviations that lead to exclusion. These analyses were repeated for the full analysis set, which included participants who received at least one dose of study treatment and had post-vaccination immunogenicity data. As only 23 participants were eliminated from the full analysis set (see Figure 1), only data for the per-protocol set are presented. Participant flow chart. 4CMenB, 4-component meningococcal serogroup B vaccine; AE, adverse event; FAS, full analysis set; MenACWY, meningococcal serogroups A, C, W, Y glycoconjugate vaccine; N, number of participants; PPS, per-protocol set. All analyses were performed on Domino platform using SAS. Results Participants Of 945 adolescents enrolled in the study, 940 were randomized to treatment (of which two were not vaccinated), and 879 completed the study (Figure 1). The most frequent reasons for not completing the study were lost to follow-up (28 participants, 3.0%) and consent withdrawal not due to an AE (20 participants, 2.1%). Of 919 participants who received study treatment and had post-vaccination immunogenicity data (full analysis set), 896 were included in the per-protocol set. The most common reasons for elimination from the per-protocol set were eligibility criteria not met (eight participants, 0.9%) and no biological sample obtained (four participants, 0.4%). The safety follow-up period was 6 months after the last vaccination for 673 participants, and 12 months after the last vaccination for 265 participants. The demographic characteristics of participants were balanced between groups (Supplemental Table S1). Overall, 827 (88.2%) participants who received at least one vaccine dose were from the US and 111 (11.8%) were from Italy. Immunogenicity The co-primary immunogenicity endpoints were met. Non-inferiority of 4CMenB co-administered with MenACWY-CRM versus 4CMenB alone was demonstrated for each of the four MenB indicator strains at 1 month after the second 4CMenB dose (day 91), with LLs of the 95% CI for between-group ratio of hSBA GMTs >0.5 for each MenB indicator strain (Figure 2(a), Table 1). Non-inferiority of MenACWY-CRM co-administered with 4CMenB versus MenACWY-CRM alone was also demonstrated at 1 month after the single MenACWY-CRM dose (day 31), with LLs of the 95% CI for between-group ratio of hSBA GMTs >0.5 for serogroups A, C, W, and Y (Figure 2(b), Table 1). Results were similar in a sensitivity analysis (to account for possible imbalances in baseline titer among groups) of adjusted hSBA GMT and between-group GMT ratios against each of the four MenB indicator strains at days 31 and 91, as were the sensitivity analysis results for serogroups A, C, W, and Y at day 31 (Supplemental Table S2). Demonstrated non-inferiority of immune responses following 4CMenB and MenACWY-CRM administered concomitantly to each vaccine alone (per-protocol set). (a) Non-inferiority to 4CMenB alone: between-group ratios of hSBA GMTs for 4 serogroup B indicator strains. (b) Non-inferiority to MenACWY-CRM alone: between-group ratios of hSBA GMTs for serogroups A, C, W, and Y. 4CMenB, 4-component meningococcal serogroup B vaccine; CI, confidence interval; fHbp, factor H binding protein; GMT, geometric mean titer; hSBA, human serum bactericidal assay; LL, lower limit; Men, meningococcal serogroup; MenACWY-CRM, meningococcal serogroups A, C, W, Y glycoconjugate vaccine; NadA, Neisseria adhesin A; NHBA, neisserial heparin-binding antigen; NI, noninferiority; PorA, Porin A. Table 1.hSBA GMTs against each meningococcal serogroup B indicator strain and group ratios at 1 month after two 4CMenB doses (study day 91) and against meningococcal serogroups A, C, W, and Y at 1 month after the single MenACWY-CRM dose (day 31) (per-protocol set). TimepointNGMT (95% CI)NGMT (95% CI)Group GMT ratio (95% CI)Indicator strain4CMenB+MenACWY group4CMenB group fHbpDay 9127416.9 (14.4, 19.8)26618.7 (15.9, 21.9)0.90 (0.77, 1.06)NadADay 91274239.6 (202.9, 283.0)267272.4 (231.1, 321.0)0.88 (0.75, 1.04)NHBADay 9127319.0 (15.6, 23.1)26620.5 (16.9, 24.9)0.93 (0.76, 1.12)PorADay 9127318.8 (15.6, 22.6)26621.3 (17.7, 25.6)0.88 (0.73, 1.06)Serogroup4CMenB+MenACWY groupMenACWY group ADay 312902388.8 (1977.2, 2886.1)2922536.1 (2095.7, 3069.1)0.94 (0.78, 1.14)CDay 312952075.9 (1602.5, 2689.3)3021867.6 (1438.7, 2424.2)1.11 (0.86, 1.44)WDay 312952299.3 (1902.5, 2778.9)3032305.7 (1905.3, 2790.4)1.00 (0.82, 1.21)YDay 312952897.3 (2359.2, 3558.3)3032802.0 (2278.3, 3446.2)1.03 (0.84, 1.27)4CMenB, 4-component meningococcal serogroup B vaccine; CI, confidence interval; fHbp, factor H binding protein; GMT, geometric mean titer; hSBA, human serum bactericidal assay; MenACWY, meningococcal serogroups A, C, W, Y glycoconjugate vaccine, MenACWY-CRM; N, number of participants with available results; NadA, Neisseria adhesin A; NHBA, neisserial heparin-binding antigen; PorA, Porin A. hSBA GMTs against each meningococcal serogroup B indicator strain and group ratios at 1 month after two 4CMenB doses (study day 91) and against meningococcal serogroups A, C, W, and Y at 1 month after the single MenACWY-CRM dose (day 31) (per-protocol set). 4CMenB, 4-component meningococcal serogroup B vaccine; CI, confidence interval; fHbp, factor H binding protein; GMT, geometric mean titer; hSBA, human serum bactericidal assay; MenACWY, meningococcal serogroups A, C, W, Y glycoconjugate vaccine, MenACWY-CRM; N, number of participants with available results; NadA, Neisseria adhesin A; NHBA, neisserial heparin-binding antigen; PorA, Porin A. Antibody hSBA GMRs 1 month after two 4CMenB doses versus baseline for each MenB indicator strain were comparable between the 4CMenB+MenACWY and 4CMenB groups, although point estimates were slightly lower in the co-administration group (Table 2). Percentages of participants with four-fold rises against MenB indicator strains after two 4CMenB doses ranged from 51.5% (PorA) to 96.0% (NadA) in the 4CMenB+MenACWY group and 53.0% (NHBA) to 98.9% (NadA) in the 4CMenB group (Table 3). The group differences show slightly lower rises in the co-administration group than in the 4CMenB group (Table 3). Similarly, for percentages of participants with hSBA titers ≥LLOQ against each MenB indicator strain and all strains combined (composite endpoint), point estimates were slightly lower in the 4CMenB+MenACWY group than in the 4CMenB group 1 month after the second 4CMenB dose (Table 3). Immune response results after one 4CMenB dose are provided in Supplemental Tables S3–S5. Table 2.hSBA geometric mean ratios compared to baseline and group ratios for each meningococcal serogroup B indicator strain at 1 month after two 4CMenB doses (study day 91) and against meningococcal serogroups A, C, W, and Y at 1 month after the single MenACWY-CRM dose (day 31) (per-protocol set). TimepointNGMR (95% CI)NGMR (95% CI)Group GMR ratio (95% CI)Indicator strain 4CMenB+MenACWY group4CMenB group fHbpDay 912746.4 (5.5, 7.5)2667.0 (5.9, 8.1)0.92 (0.79, 1.08)NadADay 9127430.7 (25.8, 36.6)26735.1 (29.5, 41.7)0.88 (0.74, 1.04)NHBADay 912735.2 (4.4, 6.2)2665.6 (4.7, 6.6)0.94 (0.79, 1.12)PorADay 912736.0 (5.0, 7.2)2666.9 (5.8, 8.3)0.88 (0.73, 1.05)Serogroup 4CMenB+MenACWY group MenACWY group ADay 31290150.2 (120.1, 187.8)292145.0 (115.4, 182.2)1.04 (0.82, 1.31)CDay 31295130.0 (97.7, 173.1)302131.9 (98.8, 176.1)0.99 (0.74, 1.32)WDay 31295294.2 (229.0, 378.1)303279.3 (216.6, 360.1)1.05 (0.82, 1.36)YDay 31295324.3 (252.2, 417.0)303300.0 (232.9, 386.4)1.08 (0.84, 1.40)4CMenB, 4-component meningococcal serogroup B vaccine; CI, confidence interval; fHbp, factor H binding protein; GMR, geometric mean ratio; hSBA, human serum bactericidal assay; MenACWY, meningococcal serogroups A, C, W, Y glycoconjugate vaccine, MenACWY-CRM; N, number of participants with available results; NadA, Neisseria adhesin A; NHBA, neisserial heparin-binding antigen; PorA, Porin A. hSBA geometric mean ratios compared to baseline and group ratios for each meningococcal serogroup B indicator strain at 1 month after two 4CMenB doses (study day 91) and against meningococcal serogroups A, C, W, and Y at 1 month after the single MenACWY-CRM dose (day 31) (per-protocol set). 4CMenB, 4-component meningococcal serogroup B vaccine; CI, confidence interval; fHbp, factor H binding protein; GMR, geometric mean ratio; hSBA, human serum bactericidal assay; MenACWY, meningococcal serogroups A, C, W, Y glycoconjugate vaccine, MenACWY-CRM; N, number of participants with available results; NadA, Neisseria adhesin A; NHBA, neisserial heparin-binding antigen; PorA, Porin A. Table 3.Percentages of participants with four-fold rises in hSBA titer and hSBA titers ≥lower limit of quantitation against each meningococcal serogroup B indicator strain at 1 month after two 4CMenB doses (study day 91) and group differences (per-protocol set). 4CMenB+MenACWY group4CMenB group Indicator strainTimepointNn% (95% CI)Nn% (95% CI)Group difference, % (95% CI)Four-fold rises in hSBA titerfHbpDay 9127315657.1 (51.0, 63.1)26317064.6 (58.5, 70.4)−7.50 (−15.66, 0.78)NadADay 9127326296.0 (92.9, 98.0)26526298.9 (96.7, 99.8)−2.90 (−6.08, −0.24)NHBADay 9127215055.1 (49.0, 61.2)26614153.0 (46.8, 59.1)2.14 (−6.27, 10.53)PorADay 9127214051.5 (45.4, 57.5)26515056.6 (50.4, 62.7)−5.13 (−13.49, 3.30)hSBA titers ≥LLOQ*fHbpBaseline296103.4 (1.6, 6.1)293258.5 (5.6, 12.3)−5.15 (−9.28, −1.40) Day 9127425392.3 (88.5, 95.2)26624692.5 (88.6, 95.3)−0.15 (−4.74, 4.48)NadABaseline296227.4 (4.7, 11.0)294268.8 (5.9, 12.7)−1.41 (−5.97, 3.09) Day 9127427399.6 (98.0, 100)26726699.6 (97.9, 100)0.01 (−1.70, 1.76)NHBABaseline2963110.5 (7.2, 14.5)2964113.9 (10.1, 18.3)−3.38 (−8.75, 1.92) Day 9127323084.2 (79.4, 88.4)26624090.2 (86.0, 93.5)−5.98 (−11.70, −0.34)PorABaseline29651.7 (0.6, 3.9)29582.7 (1.2, 5.3)−1.02 (−3.78, 1.53) Day 9127322783.2 (78.2, 87.4)26622685.0 (80.1, 89.0)−1.81 (−8.04, 4.43)CompositeBaseline29631.0 (0.2, 2.9)29231.0 (0.2, 3.0)−0.01 (−2.08, 2.03) Day 9127319772.2 (66.4, 77.4)26619974.8 (69.1, 79.9)−2.65 (−10.09, 4.82)*LLOQ: 5 for fHbp, 14 for NadA, 6 for NHBA, 6 for PorA.4CMenB, 4-component meningococcal serogroup B vaccine; CI, confidence interval; fHbp, factor H binding protein; hSBA, human serum bactericidal assay; LLOQ, lower limit of quantitation; MenACWY, meningococcal serogroups A, C, W, Y glycoconjugate vaccine; N, number of participants with available results; n, number of participants in category; NadA, Neisseria adhesin A; NHBA, neisserial heparin-binding antigen; PorA, Porin A. Percentages of participants with four-fold rises in hSBA titer and hSBA titers ≥lower limit of quantitation against each meningococcal serogroup B indicator strain at 1 month after two 4CMenB doses (study day 91) and group differences (per-protocol set). *LLOQ: 5 for fHbp, 14 for NadA, 6 for NHBA, 6 for PorA. 4CMenB, 4-component meningococcal serogroup B vaccine; CI, confidence interval; fHbp, factor H binding protein; hSBA, human serum bactericidal assay; LLOQ, lower limit of quantitation; MenACWY, meningococcal serogroups A, C, W, Y glycoconjugate vaccine; N, number of participants with available results; n, number of participants in category; NadA, Neisseria adhesin A; NHBA, neisserial heparin-binding antigen; PorA, Porin A. One month after the single MenACWY-CRM dose, hSBA GMRs versus baseline were comparable between the 4CMenB+MenACWY and MenACWY groups (Table 2) and percentages of participants with 4-fold rises against serogroups A, C, W, and Y were >95.0% and comparable between these groups (Table 4). Percentages of participants with hSBA titers ≥LLOQ against each serogroup were also high (>98.0%) and comparable between groups (Table 4). Table 4.Percentages of participants with four-fold rises in hSBA titer and hSBA titers ≥lower limit of quantitation against serogroups A, C, W, and Y at 1 month after the single MenACWY-CRM dose (day 31), and group differences (per-protocol set). 4CMenB+MenACWY group4CMenB group SerogroupTimepointNn% (95% CI)Nn% (95% CI)Group difference, % (95% CI)Four-fold rises in hSBA titerADay 3126225898.5 (96.1, 99.6)26225798.1 (95.6, 99.4)0.38 (−2.19, 3.05)CDay 3129327995.2 (92.1, 97.4)29628395.6 (92.6, 97.6)−0.39 (−3.98, 3.16)WDay 3129128798.6 (96.5, 99.6)29228697.9 (95.6, 99.2)0.68 (−1.68, 3.21)YDay 3129028698.6 (96.5, 99.6)29629198.3 (96.1, 99.4)0.31 (−2.01, 2.69)hSBA titers ≥ LLOQ*ABaseline2677528.1 (22.8, 33.9)2738230.0 (24.7, 35.9)−1.95 (−9.59, 5.73) Day 3129028999.7 (98.1, 100)29229099.3 (97.5, 99.9)0.34 (−1.30, 2.15)CBaseline29413646.3 (40.5, 52.1)29713244.4 (38.7, 50.3)1.81 (−6.20, 9.81) Day 3129529299.0 (97.1, 99.8)30229898.7 (96.6, 99.6)0.31 (−1.78, 2.46)WBaseline2928027.4 (22.4, 32.9)2928328.4 (23.3, 34.0)−1.03 (−8.30, 6.26) Day 31295295100 (98.8, 100)303303100 (98.8, 100)0.00 (−1.29, 1.25)YBaseline2916823.4 (18.6, 28.7)2966823.0 (18.3, 28.2)0.39 (−6.45, 7.25) Day 3129529499.7 (98.1, 100)30330299.7 (98.2, 100)−0.01 (−1.59, 1.54)*LLOQ: 12 for A, 8 for C, 8 for W, 10 for Y.4CMenB, 4-component meningococcal serogroup B vaccine; CI, confidence interval; hSBA, human serum bactericidal assay; LLOQ, lower limit of quantitation; MenACWY, meningococcal serogroups A, C, W, Y glycoconjugate vaccine, MenACWY-CRM; N, number of participants with available results; n, number of participants in category. Percentages of participants with four-fold rises in hSBA titer and hSBA titers ≥lower limit of quantitation against serogroups A, C, W, and Y at 1 month after the single MenACWY-CRM dose (day 31), and group differences (per-protocol set). *LLOQ: 12 for A, 8 for C, 8 for W, 10 for Y. 4CMenB, 4-component meningococcal serogroup B vaccine; CI, confidence interval; hSBA, human serum bactericidal assay; LLOQ, lower limit of quantitation; MenACWY, meningococcal serogroups A, C, W, Y glycoconjugate vaccine, MenACWY-CRM; N, number of participants with available results; n, number of participants in category. Immunogenicity analyses using the full analysis set showed results similar to those on the per-protocol set (data not shown). Safety In the 7-day period following any vaccination, at least one solicited AE was reported by 93.9% (95% CI: 90.6–96.3) of participants in the 4CMenB+MenACWY group, 94.8% (91.7–97.0) in the 4CMenB group, and 88.1% (84.1–95.1) in the MenACWY group. Percentages in each group reporting solicited local AEs at the 4CMenB injection site were higher than for the MenACWY-CRM injection site (Tables 5 and 6, Supplemental Tables S6 and S7). Percentages of participants reporting at least one solicited systemic AE were comparable among groups (Table 5). After the first study visit, solicited AEs were reported by 90.3% (86.5–93.4) of participants after receiving concomitantly administered 4CMenB and MenACWY-CRM, 92.2% (88.6–94.9) after 4CMenB, and 64.7% (59.2–69.9) after MenACWY-CRM (Table 5). Table 5.Percentage of participants who received at least one vaccine dose reporting solicited local and systemic adverse events (AEs) during the 7-day post-vaccination period. 4CMenB+MenACWY group (N = 310)4CMenB group (N = 308)MenACWY group (N = 320) n% (95% CI)n% (95% CI)n% (95% CI)Any vaccinationAny solicited AE29193.9 (90.6, 96.3)29294.8 (91.7, 97.0)28288.1 (84.1, 91.5)Local AE: 4CMenB injection site27990.0 (86.1, 93.1)27990.6 (86.8, 93.6)25479.4 (74.5, 83.7)Local AE: MenACWY-CRM injection site9631.0 (25.9, 36.4)4314.0 (10.3, 18.3)10633.1 (28.0, 38.6)Local AE: Placebo injection site258.1 (5.3, 11.7)7825.3 (20.6, 30.6)7924.7 (20.1, 29.8)Systemic AE22572.6 (67.3, 77.5)22472.7 (67.4, 77.6)22871.3 (66.0, 76.1)After vaccination at study visit 1 Any solicited AE28090.3 (86.5, 93.4)28492.2 (88.6, 94.9)20764.7 (59.2, 69.9)Local AE: 4CMenB injection site24880.0 (75.1, 84.3)25081.2 (76.3, 85.4)00Local AE: MenACWY-CRM injection site9631.0 (25.9, 36.4)0010633.1 (28.0, 38.6)Local AE: Placebo injection site007825.3 (20.6, 30.6)7924.7 (20.1, 29.8)Systemic AE17456.1 (50.4, 61.7)18459.7 (54.0, 65.3)17755.3 (49.7, 60.8)4CMenB, 4-component meningococcal serogroup B vaccine; CI, confidence interval; MenACWY, meningococcal serogroups A, C, W, Y glycoconjugate vaccine, MenACWY-CRM; N, number of participants in group; n, number of participants in category. Percentage of participants who received at least one vaccine dose reporting solicited local and systemic adverse events (AEs) during the 7-day post-vaccination period. 4CMenB, 4-component meningococcal serogroup B vaccine; CI, confidence interval; MenACWY, meningococcal serogroups A, C, W, Y glycoconjugate vaccine, MenACWY-CRM; N, number of participants in group; n, number of participants in category. Table 6.Percentage of participants who reported solicited local adverse events (AEs), by type of vaccine injection site, and solicited systemic AEs during any 7-day post-vaccination period. 4CMenB+MenACWY group (N = 309*)4CMenB group (N = 308*)MenACWY group (N = 320*) AnySevereAnySevereAnySevere n% (95% CI)n% (95% CI)n% (95% CI)n% (95% CI)n% (95% CI)n% (95% CI)Local AEs: Injection siteErythema: 4CMenB site258.1 (5.3, 11.7)00278.8 (5.9, 12.5)20.7 (0.1, 2.3)206.6 (4.1, 10.0)10.3 (0.0, 1.8)Erythema: MenACWY site51.6 (0.5, 3.8)0041.5 (0.4, 3.8)0061.9 (0.7, 4.0)00Induration: 4CMenB site258.1 (5.3, 11.7)20.6 (0.1, 2.3)3310.7 (7.5, 14.8)00144.6 (2.6, 7.7)00Induration: MenACWY site72.3 (0.9, 4.6)0010.4 (0.0, 2.1)0072.2 (0.9, 4.5)20.6 (0.1, 2.2)Pain: 4CMenB site27890.0 (86.1, 93.1)268.4 (5.6, 12.1)27689.9 (86.0, 93.0)3110.1 (7.0, 14.0)25484.1 (79.5, 88.0)289.3 (6.2, 13.1)Pain: MenACWY site9330.3 (25.2, 35.8)20.7 (0.1, 2.3)3914.7 (10.7, 19.6)0010432.6 (27.5, 38.0)10.3 (0.0, 1.7)Swelling: 4CMenB site268.4 (5.6, 12.1)31.0 (0.2, 2.8)289.1 (6.1, 12.9)10.3 (0.0, 1.8)196.3 (3.8, 9.7)10.3 (0.0, 1.8)Swelling: MenACWY site51.6 (0.5, 3.8)10.3 (0.0, 1.8)51.9 (0.6, 4.3)0051.6 (0.5, 3.6)10.3 (0.0, 1.7)Systemic AEsArthralgia4715.2 (11.4, 19.7)20.6 (0.1, 2.3)4614.9 (11.1, 19.4)20.6 (0.1, 2.3)5818.1 (14.1, 22.8)20.6 (0.1, 2.2)Fatigue15148.9 (43.2, 54.6)82.6 (1.1, 5.0)15951.6 (45.9, 57.3)92.9 (1.3, 5.5)15949.7 (44.1, 55.3)123.8 (2.0, 6.5)Headache17657.0 (51.2, 62.6)72.3 (0.9, 4.6)18359.4 (53.7, 64.9)113.6 (1.8, 6.3)18457.5 (51.9, 63.0)144.4 (2.4, 7.2)Myalgia7223.3 (18.7, 28.4)51.6 (0.5, 3.7)8026.0 (21.2, 31.3)72.3 (0.9, 4.6)8626.9 (22.1, 32.1)72.2 (0.9, 4.5)Nausea7423.9 (19.3, 29.1)51.6 (0.5, 3.7)8828.6 (23.6, 34.0)72.3 (0.9, 4.6)8927.8 (23.0, 33.1)20.6 (0.1, 2.2)Fever113.6 (1.8, 6.3)10.3 (0.0, 1.8)206.5 (4.0, 9.9)10.3 (0.0, 1.8)134.1 (2.2, 6.8)00*Number of participants in analysis of 4CMenB injection site data, N = 309, 307, and 302 for 4CMenB+MenACWY, 4CMenB, and MenACWY group, respectively. For analysis of MenACWY injection site data, N = 307, 264–266, and 319 for 4CMenB+MenACWY, 4CMenB, and MenACWY group, respectively.4CMenB, 4-component meningococcal serogroup B vaccine; CI, confidence interval; MenACWY, meningococcal serogroups A, C, W, Y glycoconjugate vaccine; N, number of participants in group; n, number of participants in category.Severe defined as preventing normal everyday activity or, for induration, swelling, and erythema, diameter >100 mm, or, for fever, body temperature ≥40°C. Percentage of participants who reported solicited local adverse events (AEs), by type of vaccine injection site, and solicited systemic AEs during any 7-day post-vaccination period. *Number of participants in analysis of 4CMenB injection site data, N = 309, 307, and 302 for 4CMenB+MenACWY, 4CMenB, and MenACWY group, respectively. For analysis of MenACWY injection site data, N = 307, 264–266, and 319 for 4CMenB+MenACWY, 4CMenB, and MenACWY group, respectively. 4CMenB, 4-component meningococcal serogroup B vaccine; CI, confidence interval; MenACWY, meningococcal serogroups A, C, W, Y glycoconjugate vaccine; N, number of participants in group; n, number of participants in category. Severe defined as preventing normal everyday activity or, for induration, swelling, and erythema, diameter >100 mm, or, for fever, body temperature ≥40°C. The most frequently reported solicited local AE after 4CMenB and MenACWY-CRM was pain and the most frequently reported solicited systemic event was headache in each group (Table 6 , Figure 3, Supplemental Table S7). Most solicited AEs were mild to moderate in intensity and transient, with a mean duration ≤4.5 d across groups. Other than severe pain at the 4CMenB injection site (reported by 8.4% of participants in 4CMenB+MenACWY group, 10.1% in 4CMenB group, and 9.3% in MenACWY group after vaccination at any visit) and severe headache in the MenACWY group (reported by 2.3%, 3.6%, and 4.4% of participants, respectively), severe AEs reported in <4% of participants in each group (Table 6). Fever ≥40°C was reported for one participant in the 4CMenB+MenACWY group after 4CMenB and MenACWY-CRM co-administration and one participant in the 4CMenB group after 4CMenB and placebo co-administration. Percentages of participants reporting each solicited local adverse event by vaccine injection site (graph a) and each solicited systemic adverse event (graph b) during the 7-day period after vaccination at study visit 1. Severe defined as preventing normal everyday activity or, for induration, swelling, and erythema, diameter >100 mm, or, for fever, body temperature ≥40°C. 4CMenB, 4-component meningococcal serogroup B vaccine; AE, adverse event; CI, confidence interval; MenACWY, meningococcal serogroups A, C, W, Y glycoconjugate vaccine. During the 12-month follow-up, unsolicited AEs were reported by 49.0% (95% CI: 43.3–54.7) of participants in the 4CMenB+MenACWY group, 50.6% (44.9–56.4) in the 4CMenB group, and 47.8% (42.2–53.4) in the MenACWY group (Table 7). Unsolicited AE data for the subset of participants that was followed for 6 months also showed no major differences between groups in safety reporting patterns. During the 30-day follow-up period after each vaccination, related unsolicited AEs were reported by 2.6% (1.1–5.0), 2.3% (0.9–4.6), and 2.2% (0.9–4.5) of participants, respectively, after the first vaccinations; 1.7% (0.5–3.8), 1.7% (0.5–3.9), and 1.9% (0.7–4.2) of participants, respectively, after the second vaccinations; and 1.7% (0.5–3.9), 1.0% (0.2–3.0), and 0.3% (0.0–1.8) of participants, respectively, after the third vaccinations. Each of the related unsolicited AEs (by preferred term) were reported by no more than one participant, apart from injection site bruising in the 4CMenB+MenACWY group (after placebo dose), rash in the 4CMenB group (after first 4CMenB dose), and chills in the MenACWY group (after first 4CMenB dose), which were reported by two participants each. Table 7.Percentage of participants who received at least one vaccine dose reporting unsolicited adverse events (AEs) during the 12-month study period. 4CMenB+MenACWY group (N = 310)4CMenB group (N = 308)MenACWY group (N = 320) n% (95% CI)n% (95% CI)n% (95% CI)Any unsolicited AE15249.0 (43.3, 54.7)15650.6 (44.9, 56.4)15347.8 (42.2, 53.4)Serious unsolicited AE20.6 (0.1, 2.3)41.3 (0.4, 3.3)72.2 (0.9, 4.5)Medically attended unsolicited AE9631.0 (25.9, 36.4)10935.4 (30.1, 41.0)10131.6 (26.5, 37.0)Unsolicited AE leading to withdrawal000010.3 (0.0, 1.7)Related unsolicited AE185.8 (3.5, 9.0)134.2 (2.3, 7.1)134.1 (2.2, 6.8)Serious related unsolicited AE000000Fatal unsolicited AE000000AEs of special interest0000004CMenB, 4-component meningococcal serogroup B vaccine; CI, confidence interval; MenACWY, meningococcal serogroups A, C, W, Y glycoconjugate vaccine; N, number of participants in group; n, number of participants in category. Percentage of participants who received at least one vaccine dose reporting unsolicited adverse events (AEs) during the 12-month study period. 4CMenB, 4-component meningococcal serogroup B vaccine; CI, confidence interval; MenACWY, meningococcal serogroups A, C, W, Y glycoconjugate vaccine; N, number of participants in group; n, number of participants in category. During the 12-month follow-up, SAEs were reported in two participants (0.6%) in the 4CMenB+MenACWY group, four (1.3%) in the 4CMenB group, and seven (2.2%) in the MenACWY group (Table 7). None was assessed as causally related to vaccination. There were no deaths. The percentage of participants reporting a medically attended unsolicited AE was 31.0% in the 4CMenB+MenACWY group, 35.4% in the 4CMenB group, and 31.6% in the MenACWY group (Table 7). One participant in the MenACWY group reported an AE leading to withdrawal (pain in extremity), which was not related to vaccination, in the 30-day period after MenACWY-CRM administration. This was also reported as an SAE due to hospitalization of the participant and resolved 7 d after onset with no definitive cause identified. The event was considered to be related to severe acute respiratory syndrome coronavirus 2 infection and corresponding pain in the thorax 4 months before vaccination. The suspected diagnosis was myocarditis and mitral valve prolapse, secondary to long COVID. No AEs of special interest were reported. Discussion This phase 3b, multicenter, observer-blind study was the first to assess concomitant administration of 4CMenB and MenACWY-CRM in healthy adolescents who had received MenACWY vaccination at least 4 y before the study start. In three parallel study groups, immunogenicity was evaluated in participants who received 4CMenB co-administered with MenACWY-CRM, two 4CMenB doses, or a single MenACWY-CRM dose. Both co-primary endpoints were met: immune responses elicited by 4CMenB and MenACWY-CRM vaccines when co-administered were non-inferior to those induced by 4CMenB alone and by a single dose of MenACWY-CRM. The immune responses against each of the MenB indicator strains after two 4CMenB doses showed no major differences between the 4CMenB+MenACWY and 4CMenB groups in terms of GMR post-vaccination versus baseline, and percentages of participants with four-fold rises in hSBA titers and with hSBA titers ≥LLOQ. Similarly, immune responses against serogroups A, C, W, and Y 1 month after the single MenACWY-CRM dose were comparable between the groups given 4CMenB plus MenACWY-CRM versus MenACWY-CRM alone. This shows that immune responses after vaccine co-administration were comparable to those following individual vaccine administration. This is consistent with the pattern seen in a phase 3b study where infants/toddlers received 4CMenB alone, MenACWY-CRM alone, or 4CMenB co-administered with MenACWY-CRM at 3, 5, 7, and 13 months of age.12 In this study, immunogenicity associated with co-administration was non-inferior to that with 4CMenB or MenACWY-CRM administered alone. The 4CMenB and MenACWY-CRM vaccines were well tolerated when co-administered or administered alone to adolescents, with no safety concerns identified and safety profiles consistent with the known safety profiles of the individual vaccines.11,28 Higher rates of solicited local AEs were reported after 4CMenB administration than after MenACWY-CRM alone, which was in line with findings from other studies in infants and older age groups.12,28 The safety profiles of 4CMenB and MenACWY-CRM in our study when administered alone are also consistent with those reported in a phase 3 study of 3,651 healthy participants aged 10–25 y administered 4CMenB on a 0–6 or 0–2–6 months schedule, pentavalent MenABCWY vaccine, or control MenACWY-CRM vaccine.18 As in our study, there was no increase in frequency of solicited AEs with subsequent 4CMenB doses. Furthermore, a recent review of published clinical trials on the immunogenicity and reactogenicity of 4CMenB co-administered with other routine childhood vaccines, including meningococcal vaccines, to infants and toddlers, and co-administered with MenACWY-CRM to adults concluded that 4CMenB co-administration is not associated with significant safety concerns or clinically relevant immunological interferences.13 US ACIP recommendations at the time of study conduct highlight 16–18 y as the preferred age for MenB vaccination for adolescents,14 which was the age group enrolled in the current study. In response to a change in the FDA label for 4CMenB, in 2024 (after this study ended) ACIP updated its recommendation for 4CMenB dose schedule, extending the interval between two doses from 0 and ≥1 month to 0 and 6 months, and adding a three-dose schedule (at 0, 1–2, and 6 months) for persons aged ≥10 y at increased risk for MenB disease.29 In our study, 4CMenB was administered on a 0–2 months schedule, and only the first dose was co-administered with MenACWY-CRM in the 4CMenB+MenACWY group. Since the main purpose of this study was to evaluate the concomitant use of 4CMenB and MenACWY-CRM in adolescents, rather than to assess a particular 4CMenB schedule, we do not regard this difference from the updated ACIP recommendations as a limitation for interpreting the results. Study limitations include the 16–18 y age group, which might reduce the generalizability of the results to other age groups, although the safety and immunogenicity of 4CMenB co-administration have already been demonstrated in clinical studies conducted in young children and adults.13 Also, most participants were White (72%) and from the US (88%), which may reduce generalizability to other population groups. In conclusion, co-administration of 4CMenB and MenACWY-CRM was well tolerated in healthy individuals aged 16–18 y, and robust immune responses were induced against all MenB indicator strains and against serogroups A, C, W, and Y. These data extend knowledge on the safety and immunogenicity of 4CMenB co-administration to two age groups, infants and adolescents, at highest risk of IMD. Supplementary Material Supplemental material.docx Acknowledgments The authors thank the participants, site personnel, and investigators who took part in the study. The authors also thank GSK project team members for their contribution to the study and/or development of this manuscript, especially Stefano Lombardi and Laureano Mestra. The authors would also like to thank Enovalife Medical Communication Service Center for editorial assistance, publication coordination, and writing support (Joanne Knowles [independent medical writer]), on behalf of GSK. All authors approved the final version and had final responsibility for the decision to submit for publication. All authors had full access to all the data. Biography Pavitra Keshavan, MBBS, PhD, is a senior director in Clinical Development at GSK, Italy. Funding Statement GlaxoSmithKline funded this study and was involved in all stages of study conduct, including analysis of the data. GSK also took in charge all costs associated with the development and publication of this manuscript. Disclosure statement Alejandro Hoberman reports payments to his institution from GSK for the conduct of the study. Alejandro Hoberman also reports he is on the Board of EarSmart AI, and a scientific consultant to both EarSmart AI and Kaizen Biosciences. Peter Silas reports payments from GSK, Merck, Pfizer, Lilly and Sanofi. Judith M. Martin reports payments from GSK to her institution for the conduct of the study. Judith M. Martin also reports payments to her institution from CDC, NIH, Leidos, Moderna and Merck, and payments from IDSA. Isabelle Lechevin is employed by GSK. Mariapia Possidente is employed by GSK. Sara Manzella is employed by GSK. Luca Moraschini is employed by GSK and holds financial equities in GSK. Maria Lattanzi is employed by GSK and holds financial equities in GSK. Pavitra Keshavan is employed by GSK and holds financial equities in GSK. These authors declare no other financial and non-financial relationships and activities. Jibran Atwi has nothing to report. Rosa Prato has nothing to report. Samantha Bosis has nothing to report. These authors declare no other financial and non-financial relationships and activities and no conflicts of interest. Data availability statement Please refer to https://www.gsk-studyregister.com/en/ to access GSK’s data sharing policies and as applicable seek anonymized subject level data. Ethical statement No patient identification information was presented in this study. The study was conducted in accordance with the International Conference on Harmonization Guideline for Good Clinical Practice and the Declaration of Helsinki. Trademark statement Bexsero and Menveo are trademarks owned by or licensed to the GSK group of companies. Menactra is a trademark of Sanofi Pasteur Inc. Supplementary material Supplemental data for this article can be accessed online at https://doi.org/10.1080/21645515.2026.2683201 References Associated Data Supplementary Materials Supplemental material.docx Data Availability Statement Please refer to https://www.gsk-studyregister.com/en/ to access GSK’s data sharing policies and as applicable seek anonymized subject level data.